CCBD’s Position on Eliminating the Use of Seclusion in Educational Settings
Behavioral Disorders · 2023-02 · 48 (2) · 134-144
DOI: 10.1177/01987429211033548 ↗Kurz gefasst
Fachartikel in der Zeitschrift Behavioral Disorders, online erschienen am 20.08.2021. Verfasst von Jennifer Freeman und 6 weiteren Autor:innen. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 60 Literaturangaben.
Abstract (Originalsprache)
This document provides recommendations of the Council for Children with Behavioral Disorders (CCBD) regarding the use of seclusion in schools. It updates the CCBD’s position on this topic first published in 2009 and includes (a) key definitions, (b) a summary of problems with the use of seclusion, (c) strategies to eliminate the use of seclusion, (d) a summary of law and policy related to seclusion, (e) a summary of research on seclusion, (f) a declaration of principles, and (g) recommendations regarding the elimination of seclusion in educational settings. A parallel document provides recommendations related to the use of physical restraint procedures in educational settings, which is often associated with the use of seclusion procedures.
Zitieren
APA
Freeman, J., Peterson, R., Kern, L., Mathur, S. R., Barber, B., Power, M., & Perea, M. (2023). CCBD’s Position on Eliminating the Use of Seclusion in Educational Settings. Behavioral Disorders, 48(2), 134-144. https://doi.org/10.1177/01987429211033548
Vancouver
Freeman J, Peterson R, Kern L, Mathur SR, Barber B, Power M, et al. CCBD’s Position on Eliminating the Use of Seclusion in Educational Settings. Behavioral Disorders. 2023;48(2):134-144. doi:10.1177/01987429211033548
BibTeX
@article{Freeman2023,
author = {Freeman, Jennifer and Peterson, Reece and Kern, Lee and Mathur, Sarup R. and Barber, Brian and Power, Mara and Perea, Madison},
title = {CCBD’s Position on Eliminating the Use of Seclusion in Educational Settings},
journal = {Behavioral Disorders},
year = {2023},
volume = {48},
number = {2},
pages = {134--144},
doi = {10.1177/01987429211033548}
}
EUVIMED